COMP <GO>
AXSM vs AMRX // OPERATING MARGIN
Axsome Therapeutics Inc. (NASDAQ) VS. Amneal Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: AXSM 5
— AMRX 6
▲ OPERATING MARGIN LEADER: AMRX
LAST: $136.01 (-5.83%) • MKT CAP: $7.12B
operating-margins
-26.10%
LAST: $20.44 (-4.97%) • MKT CAP: $7.12B
operating-margins
13.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AXSM VS. AMRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AXSM | AMRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 36.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -21.90% | 14.10% | -36.00 | AMRX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 21.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.25% | 3.63% | -4.88 | AMRX | /fcf-yield <GO> |
| Operating Margin ACTIVE | -26.10% | 13.10% | -39.20 | AMRX | /operating-margins <GO> |
| Net Profit Margin | -28.70% | 2.40% | -31.10 | AMRX | /net-margins <GO> |
| Revenue Growth (YoY) | 65.50% | 8.00% | +57.50 | AXSM | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.34 | 3.83 | +1.51 | AXSM | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | AMRX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 20.5 | 51.1 | -30.60 | AMRX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.08 | +0.07 | AXSM | /macro-sensitivity <GO> |
| Forward P/E Multiple | 35.0x | 96.0x | -61.00 | AXSM | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.12B | $7.12B | $5.1M | AXSM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AXSM REV | AMRX REV | AXSM GROSS % | AMRX GROSS % | AXSM FCF | AMRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $638.5M | $3.02B | — | 36.9% | -$93.9M | $269.9M |
| FY 2024 | $385.7M | $2.79B | — | 36.5% | -$128.7M | $243.2M |
| FY 2023 | $270.6M | $2.39B | — | — | -$157.3M | $237.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AXSM // BETA 1.15
AMRX // BETA 1.08